The Master of Science (MSc) Program in Drug Regulatory Affairs and Policy is designed to train professionals in drug regulatory affairs and policy, which are critical areas for Hong Kong and Greater Bay Area development. A notable highlight in the HKSAR Policy Address 2023 is the establishment of Hong Kong Centre for Medical Products Regulation (CMPR). The HKCMPR will be dedicated to potential restructuring and strengthening of current regulatory and approval regimes for medicine, medical devices and medical technology, in order to accelerate the approving applications and launching for registration of pharmaceutical products to the market. Our program is unique for preparing students to become proficient managers and main practitioners of guidance documents, laws, and regulations for pharmaceutical companies and government agencies. Upon completion of this program, graduates will be well-equipped to assume regulator y affairs positions in pharmaceutical, biotechnology, medical device, diagnostic and healthcare products companies, as well as government agencies.
On successful completion of the program, graduates will be able to:
To qualify for admission, applicants must meet all of the following requirements. Admission is selective and meeting these minimum requirements does not guarantee admission.